Actively Recruiting
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Led by Eli Lilly and Company · Updated on 2026-05-14
60
Participants Needed
35
Research Sites
72 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo. The study drug will be administered intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last approximately 48 weeks, including screening.
CONDITIONS
Official Title
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis of non-segmental vitiligo for at least 3 months at both screening and baseline
- Body surface area involvement between 4% and 60%, excluding palms, soles, and dorsal feet
- At least 0.5% body surface area involvement on the face
- Facial Vitiligo Area Scoring Index (F-VASI) of 0.5 or higher and Total Vitiligo Area Scoring Index (T-VASI) of 3 or higher
- Disease status either active or stable at both screening and baseline
You will not qualify if you...
- Having other types of vitiligo that are not active or stable
- Active pigmentation disorders other than vitiligo
- Active inflammatory skin diseases or skin conditions interfering with vitiligo evaluation
- Superficial skin infection within 2 weeks before baseline (rescreening allowed after resolution)
- History of chronic alcohol abuse, intravenous drug abuse, or illicit drug abuse within 1 year prior to screening
- History or presence of serious or unstable cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders
- Prior use of any JAK inhibitor therapy, systemic or topical (e.g., ruxolitinib, tofacitinib, baricitinib, upadacitinib, filgotinib, lestaurtinib, pacritinib)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 35 locations
1
Medical Dermatology Specialists
Phoenix, Arizona, United States, 85006
Not Yet Recruiting
2
Saguaro Dermatology - Phoenix
Phoenix, Arizona, United States, 85008
Not Yet Recruiting
3
Center For Dermatology Clinical Research, Inc.
Fremont, California, United States, 94538
Not Yet Recruiting
4
Northridge Clinical Trials
Northridge, California, United States, 91325
Actively Recruiting
5
Cura Clinical Research - Oxnard
Oxnard, California, United States, 93030
Not Yet Recruiting
6
Cura Clinical Research - Santa Clarita - Kelly Johnson Parkway
Santa Clarita, California, United States, 91355
Not Yet Recruiting
7
Health Clinical Research, LLC
Miami, Florida, United States, 33176
Actively Recruiting
8
K2 Medical Research - Tampa
Tampa, Florida, United States, 33634
Actively Recruiting
9
Advanced Medical Research, PC.
Sandy Springs, Georgia, United States, 30328
Not Yet Recruiting
10
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, United States, 46250
Not Yet Recruiting
11
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Not Yet Recruiting
12
Revival Research Institute, LLC
Troy, Michigan, United States, 48084
Actively Recruiting
13
Stracskin
Portsmouth, New Hampshire, United States, 03801
Not Yet Recruiting
14
Equity Medical
The Bronx, New York, United States, 10455
Actively Recruiting
15
Accurate Clinical Research, Inc
Humble, Texas, United States, 77346
Not Yet Recruiting
16
Texas Dermatology and Laser Specialists - San Antonio - South New Braunfels Avenue
San Antonio, Texas, United States, 78235
Not Yet Recruiting
17
Jordan Valley Dermatology & Research Center
South Jordan, Utah, United States, 84095
Actively Recruiting
18
Clinical Research Partners, LLC
Richmond, Virginia, United States, 23226
Actively Recruiting
19
ANIMA Research
Alken, Belgium, 3570
Not Yet Recruiting
20
UZ Gent
Ghent, Belgium, 9000
Not Yet Recruiting
21
Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman
Liège, Belgium, 4000
Not Yet Recruiting
22
INTERMED Groupe Sante
Chicoutimi, Canada, G7H 7Y8
Not Yet Recruiting
23
DermEffects
London, Canada, N6H 5L5
Not Yet Recruiting
24
Dar Clinical Research - Ottawa - Hunt Club Road
Ottawa, Canada, K1V 1C1
Not Yet Recruiting
25
The Centre for Dermatology
Richmond Hill, Canada, L4B 1A5
Not Yet Recruiting
26
Research Toronto
Toronto, Canada, M4W 2N4
Not Yet Recruiting
27
SIMa Recherche
Verdun, Canada, H4G 2L8
Not Yet Recruiting
28
Peking University People's Hospital
Beijing, China, 100034
Not Yet Recruiting
29
Hangzhou Third People's Hospital
Hangzhou, China, 310009
Not Yet Recruiting
30
Shanghai Skin Disease Hospital
Shanghai, China, 200071
Not Yet Recruiting
31
The University of Hong Kong-Shenzhen Hospital
Shenzhen, China, 518053
Not Yet Recruiting
32
Centrum Badan Klinicznych PI-House sp. z o.o.
Gdansk, Poland, 80-546
Not Yet Recruiting
33
Diamond Clinic
Krakow, Poland, 31-559
Not Yet Recruiting
34
Dermedic Jacek Zdybski
Ostrowiec Świętokrzyski, Poland, 27-400
Not Yet Recruiting
35
Centrum Medyczne Ginemedica
Wroclaw, Poland, 50-414
Not Yet Recruiting
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
P
Physicians interested in becoming principal investigators please contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here